Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was founded in 2018 and is based in London, the United Kingdom.
IPO Year: 2020
Exchange: NASDAQ
Website: renalytix.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/18/2022 | $30.00 | Buy | HC Wainwright & Co. |
| 1/4/2022 | $24.00 | Buy | BTIG |
| 10/4/2021 | $28.00 | Buy | Guggenheim |
| 7/2/2021 | $38.00 | Buy | Berenberg |
HC Wainwright & Co. initiated coverage of Renalytix with a rating of Buy and set a new price target of $30.00
BTIG initiated coverage of Renalytix with a rating of Buy and set a new price target of $24.00
Guggenheim initiated coverage of Renalytix with a rating of Buy and set a new price target of $28.00
Berenberg initiated coverage of Renalytix with a rating of Buy and set a new price target of $38.00
Investec downgraded Renalytix AI from Buy to Hold
4 - Renalytix plc (0001811115) (Issuer)
3 - Renalytix plc (0001811115) (Issuer)
4 - Renalytix plc (0001811115) (Issuer)
4 - Renalytix plc (0001811115) (Issuer)
4 - Renalytix plc (0001811115) (Issuer)
4 - Renalytix plc (0001811115) (Issuer)
4 - Renalytix plc (0001811115) (Issuer)
4 - Renalytix plc (0001811115) (Issuer)
3 - Renalytix plc (0001811115) (Issuer)
4 - Renalytix plc (0001811115) (Issuer)
SC 13D/A - Renalytix plc (0001811115) (Subject)
SC 13D/A - Renalytix plc (0001811115) (Subject)
SC 13G - Renalytix plc (0001811115) (Subject)
SC 13D/A - Renalytix plc (0001811115) (Subject)
SC 13D - Renalytix plc (0001811115) (Subject)
SC 13G/A - Renalytix plc (0001811115) (Subject)
SC 13D - Renalytix plc (0001811115) (Subject)
SC 13G/A - Renalytix plc (0001811115) (Subject)
SC 13G - Renalytix plc (0001811115) (Subject)
SC 13G/A - Renalytix plc (0001811115) (Subject)
LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB:RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that as previously disclosed regarding its intention to move listing of its American Depository Shares ("ADSs") from Nasdaq to the OTC Markets Group Inc., that effective with the market open today its ADSs are now trading on the OTCQB. The Directors have considered the benefits of the Nasdaq listing against the cost of maintaining the listing and have decided to downlist the ADSs from Nasdaq, and a
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno'), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices. Through this collaboration Renalytix and Steno will in
LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the "Panel"), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings process, pending the Panel's decision, the Company's American Depositary Shares ("ADSs") will continue trading on The Nasdaq Global Market under the symbol "RNLX." At the Panel hearing, the Company intends to present a strategic plan to regain compliance with the applicable Nasdaq listing requirements. However, there can be no assurance that the Comp
LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination ("LCD") for the Company's kidneyintelX.dkd testing. The final LCD can be accessed at LCD - KidneyIntelX and KidneyIntelX.dkd Testing (L39726) (cms.gov), and is effective for dates of service on or after August 1, 2024. The established Medicare price for kidneyintelX.dkd is $950 per test. Distinct CPT Codes (Common Procedural Terminology Codes) have been established for kidneyintelX.dkd and is published in CMS' 2024 Clinical Lab Fee Schedule. The LCD specifies coverage for use of kidneyintelX.dkd for patients wit
LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage draft, performance of new direct to physician sales force, April launch of U.S. Food and Drug Administration ("FDA") De Novo authorized kidneyintelX.dkd, and release of new real
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to joi
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the "Ordinary Shares") (the "Fundraise") to DB Capital Partners Healthcare, L.P. (the "Purchaser"), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseases care. The Fundraise was conducted by way of a securities purchase agreement between the Purchaser and the Company which consists of an initial tranche of 2,666,667 Ordinary Shares initially for an
LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kidney Disease Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), published on March 13, 2024. In the release of the new guideline, timed to coincide with World Kidney Day on March 14, the KDIGO committee highlighted the role of risk prediction in guiding care for patients. In this context, KidneyIntelX is recommended for use as an externally validated tool for predicting disease progression in people with CKD
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) (the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023. The Company plans to issue another announcement following today's report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events. The Company made significant progress during the quarter in revenue generation, reimbursement coverage, the publication of real-world evidence
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) (the "Company") today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG. About RenalytixRenalytix (NASDAQ:RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field
LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, announces the appointment of Howard Doran as Chief Business Officer, effective September 1, 2023. Mr. Doran's primary responsibility will be leading the KidneyIntelX global sales effort. He is a senior executive with over 30 years of diversified general management, strategic planning, and marketing/sales experience in the diagnostics and pharmaceutical industries in domestic and international markets. Mr. Doran serv
LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the appointment of Catherine Coste to the Company's Board of Directors, effective June 30, 2023. Ms. Coste was also appointed as the Non-Executive Chair of the Audit Committee and a member of the Renumeration Committee. Ms. Coste has extensive financial experience having retired from Deloitte and Touche LLP ("Deloitte") in 2020, where she was a senior partner and served as one of Deloitte's life sciences
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
NEW YORK and SALT LAKE CITY, March 30, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ:RNLX) (LSE: RENX) today announced that, following the Company's announcement on February 22, 2022, Timothy Scannell has been appointed to the Board as an independent Non-Executive Director of Renalytix. As an accomplished leader in healthcare innovation, Mr. Scannell brings more than 30 years of experience in medical technology to the Renalytix Board, and previously served as President and C.O.O. of Stryker. Mr. Scannell currently serves as Chair of Insulet Corporation's board of directors and serves on the board of directors for Novocure and Collagen Matrix. He holds Bachelor of Business Administratio
NEW YORK and SALT LAKE CITY, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) today announced that Jean M. Casner joined the Company this week on January 3, 2022 as Senior Vice President & Chief Human Resources Officer. Ms. Casner will be responsible for Renalytix's global human resources organization, including people strategy, compensation, benefits, learning and development, diversity & inclusion, and performance and talent management. Ms. Casner joins Renalytix from her former position as Senior Vice President & CHRO at Cantel Medical, which experienced significant annual revenue growth during her tenure prior to the company being recently acquired. During her
NEW YORK and SALT LAKE CITY, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) today announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration patient population with the appointment of Jed Fulk to the position of Vice President Sales, Government Accounts. Mr. Fulk is developing and leading a team expected to grow to 42 regional sales managers and account executives during calendar year 2022 to support KidneyIntelX™ rollout to the VA Health System. KidneyIntelX will be deployed to help VA primary care physicians to identify diabetic kidney disease (DKD) patients at high and low risk for rapid progr
NEW YORK and SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ:RNLX) (LSE: RENX) today announced the appointment of Daniel J. Levangie to the Company's board of directors. Mr. Levangie is also appointed as a member of the Company's remuneration committee. Mr. Levangie is an experienced executive and long-serving board director in the diagnostics and medical devices industry. He is co-founder and manager of ATON Partners, a private investment firm, and president and CEO of CereVasc, LLC, a medical device company. He also has served on the board of directors of Exact Sciences Corporation (NASDAQ:EXAS) since 2010. From 2013 through January 2017, Mr. Levangie served as
NEW YORK and SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) today announced the appointment of Ann E. Berman to its board of directors. She will chair the board's audit committee and serve as member of the nomination committee. Ms. Berman currently serves on the board of directors and as a member of the audit committee of Loews Corporation (NYSE:L), a $14.5 billion market capitalization company with subsidiaries that include CNA Financial. In addition, Ms. Berman is a member of the board of trustees of Beth Israel Deaconess Medical Center, where she is the chair of the compliance and risk committees and Immuneering Corporation where she chairs th
NEW YORK and SALT LAKE CITY, July 22, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ:RNLX) (LSE: RENX) today announced the appointment of Joseph Hutson as its Vice President of Quality and Regulatory. Hutson brings 23 years of experience in the life sciences industry, including quality and regulatory leadership roles at Cardinal Health, CareFusion, Becton Dickinson and Abbott Diagnostics. He will lead teams focused on assuring compliance with United States and international Quality Management System regulations and standards and driving efficient approval for a series of products under the KidneyIntelX brand through review by the appropriate regulatory authorities including the United Stat
LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage draft, performance of new direct to physician sales force, April launch of U.S. Food and Drug Administration ("FDA") De Novo authorized kidneyintelX.dkd, and release of new real
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to joi
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) (the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023. The Company plans to issue another announcement following today's report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events. The Company made significant progress during the quarter in revenue generation, reimbursement coverage, the publication of real-world evidence
LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2023. Recent Highlights (including post period events) Financing discussions in process with goal to provide operating runway through at least early calendar 2026, enabled by cost reductions and sales growth from adoptions by new hospital systems and independent physiciansCost cutting initiative projected to reduce payro
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT). Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the confe
LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal year ended June 30, 2023. Recent Highlights (including post period events) Regulatory & Reimbursement Achieved FDA De Novo marketing authorization for KidneyIntelX.dkd to assess risk of progressive kidney function decline in adults with diabetes and early-stage kidney disease.Secured additional key insurance coverage contracts for KidneyIntelX inclu
LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2023. Recent Highlights (including post period events) Continued progress with FDA De Novo authorization review, with FDA indicating a target date for decision completion by the end of the second calendar quarter of 2023Secured additional key insurance coverage contracts for KidneyIntelX including: EmblemHealth, co
LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call. Webcast Reg
LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal second quarter and first half ended December 31, 2022. Recent Highlights (including post period events) Expanded insurance coverage for KidneyIntelX including: One of the largest not-for-profit health insurers covering over three million lives in the Northeast U.S.Largest private payer in Illinois with over eight million members35 state Medicaid plans i
DEF 14A - Renalytix plc (0001811115) (Filer)
PRE 14A - Renalytix plc (0001811115) (Filer)
8-K - Renalytix plc (0001811115) (Filer)
10-K - Renalytix plc (0001811115) (Filer)
8-K - Renalytix plc (0001811115) (Filer)
8-K - Renalytix plc (0001811115) (Filer)
EFFECT - Renalytix plc (0001811115) (Filer)
424B3 - Renalytix plc (0001811115) (Filer)
S-3/A - Renalytix plc (0001811115) (Filer)
8-K/A - Renalytix plc (0001811115) (Filer)